{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:40:15Z","timestamp":1782391215156,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Global human activities were significantly impacted by the emergence of the coronavirus disease 2019 (COVID-19) pandemic caused by the 2019 novel coronavirus. This study aimed to investigate the prevalence and genotype distribution of HPV infection in Central Fujian Province during the pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cervical samples were collected from 21,612 outpatients and 12,664 females who underwent physical examinations and HPV screening at the People\u2019s Hospital of Fujian Province in Fuzhou from April 2020 to April 2023. HPV detection and genotyping were conducted using PCR hybridization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall HPV infection rate was 16.1% during the COVID-19 pandemic, with the outpatient group exhibiting a greater infection rate (19.0%) than did the healthy group (12.3%). The top five high-risk HPV (HR-HPV) genotypes in both groups were HPV52, HPV53, HPV58, HPV16, and HPV51. Additionally, HPV81 and HPV43 were the two most common low-risk HPV (LR-HPV) genotypes in the patient group, while HPV81 and HPV42 were the two most common LR-HPV genotypes in the healthy group. The highest prevalence of HPV infection was observed in individuals aged\u2009\u2264\u200924 years (28.4%, 95% CI 25.9\u201330.9), followed by those aged\u2009\u2265\u200955 years (23.6%, 95% CI 21.6\u201324.7) and other age groups. The prevalence decreased from 23.0% (95% CI 22.4\u201323.7) in 2018\u20132019 to 13.8% (95% CI 12.0-15.5) in 2023.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study provides valuable insights into the prevalence and genotypes of HPV infection in the female population of Central Fujian Province from 2020 to 2023. The findings indicate that the prevalence of HPV infection in Central Fujian Province remains relatively low compared to the national average. Furthermore, the prevalence of HPV decreased during the COVID-19 pandemic; however, as the pandemic waned, there was potential for an increase in HPV infection rates. Therefore, it is crucial to strengthen HPV screening and vaccination strategies to prevent the potential spread of HPV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-024-02393-z","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:16:19Z","timestamp":1717578979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The prevalence and genotype distribution of human papillomavirus in central Fujian Province during the COVID-19 pandemic"],"prefix":"10.1186","volume":"21","author":[{"given":"Boxi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"3","key":"2393_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"385","key":"2393_CR2","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMsr2030640","volume":"20","author":"VWNMA Bouvard","year":"2021","unstructured":"Bouvard VWNMA. The IARC Perspective on Cervical Cancer Screening. N Engl J Med. 2021;20(385):1908\u201318.","journal-title":"N Engl J Med"},{"issue":"10","key":"2393_CR3","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","volume":"8","author":"LSBRE Bruni","year":"2022","unstructured":"Bruni LSBRE. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. LANCET GLOB HEALTH. 2022;8(10):e1115\u201327.","journal-title":"LANCET GLOB HEALTH"},{"issue":"127","key":"2393_CR4","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1002\/cncr.33795","volume":"21","author":"SGKGS Lin","year":"2021","unstructured":"Lin SGKGS. Worldwide trends in Cervical Cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;21(127):4030\u20139.","journal-title":"Cancer"},{"issue":"69","key":"2393_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"1","author":"RLMKJA Siegel","year":"2019","unstructured":"Siegel RLMKJA. Cancer statistics, 2019. CA Cancer J Clin. 2019;1(69):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2393_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. INT J CANCER. 2017;141(4):664\u201370.","journal-title":"INT J CANCER"},{"key":"2393_CR7","doi-asserted-by":"crossref","unstructured":"Bzhalava DECDJ. International standardization and classification of human papillomavirus types. Virology 2015(476):341\u20134.","DOI":"10.1016\/j.virol.2014.12.028"},{"issue":"10221","key":"2393_CR8","first-page":"312","volume":"395","author":"T Lancet","year":"2020","unstructured":"Lancet T. New health indicators for America: aiming to shift practice. Lancet (British Edition). 2020;395(10221):312.","journal-title":"Lancet (British Edition)"},{"issue":"1","key":"2393_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12985-023-01959-7","volume":"20","author":"W Zhang","year":"2023","unstructured":"Zhang W, Guo N, Li B, Shang E, Wang J, Zhang M, Yang X. Prevalence and genotype distribution of human papillomavirus infections in Beijing, China between 2016 and 2020. VIROL J. 2023;20(1):11.","journal-title":"VIROL J"},{"issue":"1","key":"2393_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12985-021-01676-z","volume":"18","author":"X Yan","year":"2021","unstructured":"Yan X, Shen L, Xiao Y, Wang Q, Li F, Qian Y. Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016\u20132020. VIROL J. 2021;18(1):208.","journal-title":"VIROL J"},{"issue":"1","key":"2393_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12889-017-4651-7","volume":"18","author":"C Wu","year":"2017","unstructured":"Wu C, Zhu X, Kang Y, Cao Y, Lu P, Zhou W, Zhou H, Zhang Y, Song Y. Epidemiology of Humanpapilloma virus infection among women in Fujian, China. BMC Public Health. 2017;18(1):95.","journal-title":"BMC Public Health"},{"issue":"19","key":"2393_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12985-022-01879-y","volume":"1","author":"XXFDJ Li","year":"2022","unstructured":"Li XXFDJ. Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China. Virol J. 2022;1(19):146.","journal-title":"Virol J"},{"issue":"17","key":"2393_CR13","first-page":"5439","volume":"12","author":"XSGLY Han","year":"2021","unstructured":"Han XSGLY. Prevalence and genotype distribution of human papillomavirus infection among women aged 30\u201365 years in Xi\u2019 an, China: a population-based study of 14,655 women. Hum Vaccin Immunother. 2021;12(17):5439\u201346.","journal-title":"Hum Vaccin Immunother"},{"issue":"19","key":"2393_CR14","doi-asserted-by":"publisher","first-page":"2212571","DOI":"10.1080\/21645515.2023.2212571","volume":"1","author":"YXXZW Ma","year":"2023","unstructured":"Ma YXXZW. HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic. Hum Vaccin Immunother. 2023;1(19):2212571.","journal-title":"Hum Vaccin Immunother"},{"issue":"22","key":"2393_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12879-022-07893-3","volume":"1","author":"ZLHZJ Chen","year":"2022","unstructured":"Chen ZLHZJ. Epidemiological study of HPV infection in 40,693 women in Putian: a population study based on screening for high-risk HPV infection. BMC Infect Dis. 2022;1(22):893.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2393_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12905-021-01504-0","volume":"21","author":"W Lin","year":"2021","unstructured":"Lin W, Zhang Q, Chen Y, Chen L, Dong B, Sun P. The prevalence of human papillomavirus and bacterial vaginosis among young women in China: a cross-sectional study. BMC Womens Health. 2021;21(1):409.","journal-title":"BMC Womens Health"},{"issue":"1","key":"2393_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12985-021-01732-8","volume":"19","author":"X Wang","year":"2022","unstructured":"Wang X, Song Y, Wei X, Wang G, Sun R, Wang M, Zhao L. Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China. VIROL J. 2022;19(1):6.","journal-title":"VIROL J"},{"issue":"17","key":"2393_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13027-022-00431-5","volume":"1","author":"LMLQL Wei","year":"2022","unstructured":"Wei LMLQL. The prevalence and genotype distribution of human papillomavirus among women in Guangxi, southern China. Infect Agent Cancer. 2022;1(17):19.","journal-title":"Infect Agent Cancer"},{"issue":"7","key":"2393_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/jamaoncol.2020.6575","volume":"2","author":"JZYDY Zhang","year":"2021","unstructured":"Zhang JZYDY. Effectiveness of high-risk human papillomavirus testing for Cervical Cancer Screening in China: a Multicenter, Open label, Randomized Clinical Trial. JAMA ONCOL. 2021;2(7):263\u201370.","journal-title":"JAMA ONCOL"},{"issue":"125","key":"2393_CR20","first-page":"1030","volume":"7","author":"KLQSL Li","year":"2019","unstructured":"Li KLQSL. The distribution and prevalence of human papillomavirus in women in Mainland China. CANCER-AM CANCER SOC. 2019;7(125):1030\u20137.","journal-title":"CANCER-AM CANCER SOC"},{"issue":"17","key":"2393_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","volume":"4","author":"KACJ Szymonowicz","year":"2020","unstructured":"Szymonowicz KACJ. Biological and clinical aspects of HPV-related cancers. CANCER BIOL MED. 2020;4(17):864\u201378.","journal-title":"CANCER BIOL MED"},{"issue":"7","key":"2393_CR22","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/v13071342","volume":"13","author":"M Kim","year":"2021","unstructured":"Kim M, Park NJ, Jeong JY, Park JY. Multiple human papilloma virus (HPV) infections are Associated with HSIL and Persistent HPV infection status in Korean patients. VIRUSES-BASEL. 2021;13(7):1342.","journal-title":"VIRUSES-BASEL"},{"issue":"4","key":"2393_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/v12040380","volume":"12","author":"MA Oyervides-Mu\u00f1oz","year":"2020","unstructured":"Oyervides-Mu\u00f1oz MA, P\u00e9rez-Maya AA, S\u00e1nchez-Dom\u00ednguez CN, Berlanga-Garza A, Antonio-Macedo M, Vald\u00e9z-Chapa LD, Cerda-Flores RM, Trevino V. Barrera-Salda\u00f1a HA, Garza-Rodr\u00edguez ML: multiple HPV infections and Viral Load Association in Persistent Cervical lesions in Mexican Women. VIRUSES-BASEL. 2020;12(4):380.","journal-title":"VIRUSES-BASEL"},{"issue":"43","key":"2393_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cac2.12256","volume":"3","author":"HMLZY Bao","year":"2022","unstructured":"Bao HMLZY. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study. CANCER COMMUN. 2022;3(43):191\u2013204.","journal-title":"CANCER COMMUN"},{"issue":"19","key":"2393_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12889-019-6487-9","volume":"1","author":"YZSRM Ge","year":"2019","unstructured":"Ge YZSRM. Prevalence of human papillomavirus infection of 65,613 women in East China. BMC Public Health. 2019;1(19):178.","journal-title":"BMC Public Health"},{"issue":"36","key":"2393_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.canep.2012.01.009","volume":"4","author":"FHTSHS Zhao","year":"2012","unstructured":"Zhao FHTSHS. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China. CANCER EPIDEMIOL. 2012;4(36):384\u201390.","journal-title":"CANCER EPIDEMIOL"},{"issue":"9","key":"2393_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/jwh.2008.1223","volume":"18","author":"KN Althoff","year":"2009","unstructured":"Althoff KN, Paul P, Burke AE, Viscidi R, Sangaramoorthy M, Gravitt PE. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Women\u2019s Health (Larchmont N Y 2002). 2009;18(9):1341\u20136.","journal-title":"J Women\u2019s Health (Larchmont N Y 2002)"},{"issue":"15","key":"2393_CR28","first-page":"e230640","volume":"3","author":"SWCLS Hao","year":"2020","unstructured":"Hao SWCLS. HPV genotypic spectrum in Jilin Province, China, where non-vaccine-covered HPV53 and 51 are prevalent, exhibits a bimodal age-specific pattern. PLoS ONE. 2020;3(15):e230640.","journal-title":"PLoS ONE"},{"key":"2393_CR29","unstructured":"WHO COVID-19. pandemic fuels largest continued backslide in vaccinations in three decades.; 2022."},{"key":"2393_CR30","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2214-109X(21)00512-X","volume":"10","author":"A Shet CKDM","year":"2022","unstructured":"Shet A CKDM. Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. Lancet Glob Health. 2022;10:e186\u201394.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"2393_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20477724.2023.2239052","volume":"117","author":"R Luigi","year":"2023","unstructured":"Luigi R, Stefania S, Francesca I, Federica R, Fiore BD, Annalisa S, Francesco DG, Eugenio M, Mandorino M, Adriana M, et al. HPV and Covid-19 era: effects of nonpharmaceutical interventions on HPV transmission. PATHOG GLOB HEALTH. 2023;117(8):1\u2013743.","journal-title":"PATHOG GLOB HEALTH"},{"issue":"26","key":"2393_CR32","first-page":"7285","volume":"19","author":"SNGTG D\u2019Amato","year":"2022","unstructured":"D\u2019Amato SNGTG. Impact of the COVID-19 pandemic on HPV vaccination coverage in the general population and in PLWHs. Eur Rev Med Pharmacol Sci. 2022;19(26):7285\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2393_CR33","doi-asserted-by":"publisher","first-page":"799736","DOI":"10.3389\/fmed.2022.799736","volume":"9","author":"H Liu","year":"2022","unstructured":"Liu H, Yao Q, Li D, Zhao Z, Li Y. Impact of COVID-19 outbreak on the gynecological outpatients HPV infection rate in Wuhan, China: a retrospective observational study. FRONT MED-LAUSANNE. 2022;9:799736.","journal-title":"FRONT MED-LAUSANNE"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02393-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:20:13Z","timestamp":1717579213000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02393-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02393-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Institutional Medical Ethics Review Board of People\u2019s Hospital Affiliated of Fujian University of Traditional Chinese Medicine, Fuzhou, China (Grant NO.: 2023-60-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}